Scott Bizily - 16 Dec 2025 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role: Chief Legal Officer
Signature: /s/ Scott Bizily
Issuer symbol: FDMT
Transactions as of: 16 Dec 2025
Net transactions value: -$11,053
Form type: 4
Filing time: 19 Dec 2025, 16:10:38 UTC
Previous filing: 19 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bizily Scott	Chief Legal Officer	C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE	/s/ Scott Bizily	19 Dec 2025	0001920738

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FDMT	Common Stock	Options Exercise	$6,769	+1,635	+45%	$4.14	5,229	16 Dec 2025	Direct
transaction	FDMT	Common Stock	Sale	$17,822	-1,635	-31%	$10.90	3,594	16 Dec 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FDMT	Stock Option (Right to Buy)	Options Exercise	$0	-1,635	-2.2%	$0.000000	73,595	16 Dec 2025	Common Stock	1,635	$4.14	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
F2	The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

Content

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.